A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to compare two different anti-HIV drug combinations, one that contains nelfinavir (NFV) and one that does not. The best dosing schedule for indinavir (IDV) also will be studied.
Patients are stratified by screening plasma viral RNA results (50,000 copies/ml or below vs above 50,000 copies/ml) and randomized to 1 of 2 treatment arms. Group 1 receives IDV 3 times daily plus d4T/3TC twice daily. Group 2 receives IDV/NFV/d4T/3TC twice daily. Patients remain on study medications for 24 weeks and are seen at the clinic once every 4 weeks after entering the study. At each clinic visit, blood samples are taken to evaluate CD4 cell count and plasma HIV RNA levels.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
16 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
You may be eligible for this study if you:
Are HIV positive.
Have a viral load (level of HIV in your blood) of at least 10,000 copies/ml within 45 days of study entry.
Have a CD4 cell count of at least 100 cells/mm3 within 45 days of study entry.
Have a normal chest X-ray.
Have never taken protease inhibitors or 3TC.
Are 16 years of age or older.
Agree to practice sexual abstinence or use barrier methods of birth control (e.g., condoms).
You will not be eligible for this study if you:
Have an active opportunistic (AIDS-related) infection or cancer.